BioTuesdays

Tag - AXSM

Axsome Therapeutics
Markets

BTIG ups Axsome Therapeutics PT to $48 from $25

BTIG raised its price target for Axsome Therapeutics (NASDAQ:AXSM) to $48 from $25 after the company announced positive Phase 2 data for its AXS-12 drug candidate for the treatment of cataplexy and excessive daytime...

December 4, 2019
Axsome Therapeutics
Executive Moves

Axsome Therapeutics names David Marek as CCO

David Marek Axsome Therapeutics (NASDAQ:AXSM) has appointed David Marek as chief commercial officer, effective Aug. 31. Mr. Marek joins Axsome from Amgen (NASDAQ:AMGN), where he was most recently VP and general manager...

August 20, 2019
Axsome Therapeutics
Markets

SVB Leerink starts Axsome Therapeutics at OP; PT $25

SVB Leerink initiated coverage of Axsome Therapeutics (NASDAQ:AXSM) with an “outperform” rating and $25 price target. The stock closed at $14.50 on April 5. “The specialty pharma business model (using proprietary...

April 8, 2019